Two GHRH analogs used to stimulate the body's own growth hormone. They differ mainly in half-life and duration of action.
CJC-1295 and Sermorelin are both GHRH analogs — they prompt the pituitary to release growth hormone rather than replacing it. The practical difference is duration: the CJC-1295 'with DAC' version lasts far longer. Both are provider-territory, not FDA-approved for general optimization, and prohibited in sport.
| CJC-1295 | Sermorelin | |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Half-life | Long (DAC version binds albumin) | Short (minutes) |
| Typical use in research | Less frequent dosing | More frequent dosing |
| FDA status | Not approved for general optimization | Has historical clinical use; not for general optimization |
| Sport (WADA) | Prohibited | Prohibited |
The choice is largely about pharmacokinetics and is a clinical decision. Growth-hormone-axis manipulation requires lab monitoring and a provider who can weigh the long-term unknowns.
If you'd like help applying this information to your own health, schedule a consultation with the Bearing team.
Request a Consultation